Lopinavir/ritonavir
Combination of | |
---|---|
Lopinavir | Protease inhibitor |
Ritonavir | Protease inhibitor (pharmacokinetic booster) |
Clinical data | |
Trade names | Kaletra, Aluvia |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602015 |
License data | |
Pregnancy category |
|
By mouth | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
KEGG | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
(what is this?) (verify) |
Lopinavir/ritonavir (LPV/r), sold under the brand name Kaletra among others, is a
Common side effects include
Lopinavir/ritonavir as a single medication was approved for use in the United States in 2000.[2] It is on the World Health Organization's List of Essential Medicines.[3]
Medical uses
Lopinavir/ritonavir was once a preferred combination for HIV first-line therapy in the United States.[4] But due its higher pill burden compared to than other protease inhibitor-based regimens and increased gastrointestinal intolerance, it is no longer recommended to treatment-naive patients.[5]
Adverse effects
The most common adverse effects observed with lopinavir/ritonavir are
Raised liver enzymes and hyperlipidemia (both hypertriglyceridemia and hypercholesterolemia) are also commonly observed during lopinavir/ritonavir treatment.[citation needed]
Lopinavir/ritonavir is anticipated to have varying degrees of interaction with other medications that are also
People with a structural
On 8 March 2011 the U.S. Food and Drug Administration notified healthcare professionals of serious health problems that have been reported in premature babies receiving lopinavir/ritonavir oral solution, probably because of its propylene glycol content. They recommend the use should be avoided in premature babies.[9]
History
Lopinavir was developed by
Lopinavir/ritonavir was approved by the US Food and Drug Administration (FDA) on 15 September 2000,[12][13] and in Europe on 19 March 2001.[14] Its patent was scheduled to expire in the US on 26 June 2016.[citation needed][needs update]
In March 2020, during the
Society and culture
Cost
As a result of high prices and the spread of HIV infection, the government of
Available forms
Heat-stable pellets that can be taken by mouth have been developed for children.[21]
Research
While data for
References
- ^ "Kaletra Product information". Health Canada. 19 March 2019. Retrieved 18 March 2020.
- ^ a b c d e f g h i j k "Lopinavir and Ritonavir". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 28 November 2016.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Adult and Adolescent Guidelines". AIDSinfo. 4 May 2006. Archived from the original on 6 May 2006. Retrieved 6 May 2006.
- ^ "What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient". AIDSinfo. 18 December 2019. p. Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy. Archived from the original on 31 August 2020. Retrieved 26 August 2020.
- ^ a b "Kaletra- lopinavir and ritonavir tablet, film coated Kaletra- lopinavir and ritonavir solution". DailyMed. 26 December 2019. Retrieved 18 March 2020.
- PMID 19839641.
- ^ "FDA Issues Safety Labeling Changes for Kaletra". Medscape. 10 April 2009. Archived from the original on 10 September 2017. Retrieved 18 March 2020.
- ^ "Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies". Drugs.com. Archived from the original on 11 March 2011.
- ^ Foster C. "Research at Argonne helps Abbott Labs develop anti-HIV drug". Archived from the original on 22 October 2006. Retrieved 4 September 2006.
- ^ PMID 9835517.
- ^ "Drug Approval Package: Kaletra (Lopinavir/Ritonavir) NDA #21-226 & 21-251". U.S. Food and Drug Administration (FDA). 20 November 2001. Retrieved 18 March 2020.
- ^ "Generic Kaletra Availability". Drugs.com. Retrieved 18 February 2020.
- ^ "Kaletra EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 18 February 2020.
- ^ Bonadio E, Baldini A (1 April 2020). "Drug companies should drop their patents and collaborate to fight coronavirus". The Conversation.
- ^ "Inoculating the world may mean reviving old curbs on patents". Pittsburgh Post-Gazette. Bloomberg. 14 April 2020. Retrieved 16 April 2020.
- ^ Scheer S (19 March 2020). "Israel approves generic HIV drug to treat COVID-19 despite doubts". Reuters. Retrieved 16 April 2020.
- ^ "Decree of Department of Disease Control, Ministry of Public Health, regarding exploitation of patent on drugs & medical supplies by the government on combination drug between lopinavir & ritonavir" (PDF). Archived from the original (PDF) on 17 July 2011.
- ^ 'Abbott pulls HIV drug in Thai patents protest', Financial Times (14 March 2007)
- ^ "People Living with HIV: Let's change the rules imposed by the pharmaceutical industry!" (PDF). AIDES. 1 July 2007. Archived from the original (PDF) on 20 October 2007.
- PMID 30549217.
- ^ PMID 32284951.
- PMID 32187464.
This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with Covid-19 different from that associated with standard care alone.
External links
- "Lopinavir mixture with ritonavir". Drug Information Portal. U.S. National Library of Medicine.
- "Fact sheet on lopinavir and ritonavir (Lpv/R) oral pellets". World Health Organization (WHO). Archived from the original on 21 November 2015.